Angiotensin Receptor Blockers: Novel Role in High-Risk Patients

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 507-526

  Javed, Usman ^a   Deedwania, Prakash C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blockers; Cardioprotection; Diabetes mellitus; High risk hypertension; RAAS blockade

Indexed keywords

ADIPONECTIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; SUPEROXIDE DISMUTASE; TELMISARTAN; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETES MELLITUS; HEART DEATH; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 53149122906     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.07.001     Document Type: Review

References (90)

1. Kannel W.B. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther 11 Suppl 1 (1997) 199-212
2. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
3. Narayan K.M., Boyle J.P., Thompson T.J., et al. Lifetime risk for diabetes mellitus in the United States. JAMA 290 (2003) 1884-1890
4. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
5. Steinberger J., and Daniels S.R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107 (2003) 1448-1453
6. Hedley A., Ogden C., Johnson C., et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
7. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). National cholesterol education program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 106 (2002) 3143-3421
8. Sowers J.R. Obesity as a cardiovascular risk factor. Am J Med 115 Suppl 8A (2003) 37S-41S
9. McFarlane S.I., Jacober S.J., Winer N., et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25 (2002) 718-723
10. Williams B., Poulter N., Brown M., et al. British hypertension society guidelines for hypertension management (BHS-IV): summary. BMJ 328 (2004) 634-640
11. Neal B., Macmahon S., and Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000) 1955-1964
12. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ 336 (2008) 1121-1123
13. Casas J., Chua W., Loukogeorgakis S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
14. Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract 68 Suppl 1 (2005) S43-S47
15. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 434-444
16. Centers for Disease Control and prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005 (2005), US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA)
17. Seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
18. Lip G.Y., and beevers D.G. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHeFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 17 (2003) 747-750
19. Khaper N., and Singal P.K. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 37 (2001) 1461-1466
20. Leiter L.A., and Lewanczuk R.Z. Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18 (2005) 121-128
21. Watanabe S., Tagawa T., Yamakawa K., et al. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 25 (2005) 2376-2380
22. Unger T., Culman J., and Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 16 Suppl 7 (1998) S3-S9
23. Andraws R., and Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99 (2007) 1006-1012
24. McCall K.L., Craddock D., and Edwards K. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 26 (2006) 1297-1306
25. Tsouli S.G., Liberopoulos E.N., Kiortsis D.N., et al. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J Cardiovasc Pharmacol Ther 11 (2006) 1-15
26. Luno J., Praga M., and de Vinuesa S.G. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 11 (2005) 1291-1300
27. 2 recpetors. Blood Press 5 Suppl 2 (1996) 47-52
28. Johnston C.I., and Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 10 (1997) 306S-310S
29. Timmermans P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45 (1993) 205-251
30. Drexler H., and Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 31 (1999) 51-60
31. Britten M.B., Zeiher A.M., and Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 245 (1999) 315-327
32. Fishel R.S., Eisenberg S., Shai S.Y., et al. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension 25 (1995) 343-349
33. Brown N.J., Agirbasli M.A., Williams G.H., et al. Effect of activation and inhibition of the rennin-angiotensin system on plasma PAI-1. Hypertension 32 (1998) 965-971
34. Gainer J.V., Morrow J.D., Loveland A., et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339 (1998) 1285-1292
35. Hornig B., Kohler C., and Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95 (1997) 1115-1118
36. Diet F., Pratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94 (1996) 2756-2767
37. Willemsen J.M., Westerink J.W., Dallinga-Thie G.M., et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 49 (2007) 6-12
38. Fiordaliso F., Cuccovillo I., Bianchi R., et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 79 (2006) 121-129
39. Nascimben L., Bothwell J.H., Dominguez D.Y., et al. Angiotensin II stimulates insulin-independent glucose uptake in hypertrophied rat hearts. [abstract]. J Hypertens 15 Suppl 4 (1997) S84
40. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144 (2003) 2195-2200
41. Moule K.S., and Denton R.M. Multiple signaling pathways involved in the metabolic effects of insulin. Am J Cardiol 80 (1997) 41A-49A
42. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
43. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
44. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. The HOPE and HOPE-TOO Trial Investigators. JAMA 293 (2005) 1338-1347
45. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
46. Schorb W., Peeler T.C., Madigan N.N., et al. Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat. J Biol Chem 269 (1994) 19626-19632
47. Wan J., Kurosaki T., Huant X.Y., et al. Tyrosine kinases in activation of the MAP-kinase cascade by G protein-coupled receptors. Nature 380 (1996) 541-544
48. Saad M.J., Velloso L.A., and Carvalho C.R. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 310 (1995) 741-744
49. Bernobich E., de Angelis L., Lerin C., et al. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 62 (2002) 1295-1314
50. Higashi Y., Chayama K., and Yoshizumi M. Angiotensin II Type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem 3 (2005) 133-148
51. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
52. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
53. Seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute (2004), NIH Publication No. 04-5230
54. Julius S., Nesbitt S.D., Egan B.M., et al. The Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 16 (2006) 1685-1697
55. Schrader J., Luders S., Kulschewski A., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
56. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
57. Ikejima H., Imanishi T., Tsujioka H., et al. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 2 (2008) 964-972 [My paper]
58. Dickstein K., and Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 9335 (2002) 752-760
59. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
60. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355 9215 (2000) 1582-1587
61. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6 (2004) 937-945
62. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100 (1999) 1056-1064
63. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure. Lancet 362 (2003) 759-766
64. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
65. Yusuf S., Pfeffer M.A., and Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Preserved trial. Lancet 362 (2003) 777-781
66. McMurray J.J., Ostergen J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
67. Breener B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
68. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
69. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
70. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124 [erratum in: Lancet 2003;361:1230]
71. Bakris G.L., Ruilope L., Locatelli F., et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72 (2007) 879-885
72. Sharma A.M., Janke J., Gorzelniak K., et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 5 (2002) 609-611
73. Furuhashi M., Ura N., Takizawa H., et al. Blockade of the rennin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22 10 (2004) 1977-1982
74. Kingston R. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22 (2004) 1867-1868
75. Jandeleit-Dahm K.A., Tikellis C., Reid C.M., et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23 3 (2005) 463-473
76. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetic mellitus and insulin resistance. Am J Cardiol 93 11A (2004) 27C-31C
77. Aranda Jr. J.M., and Conti R. Angiotensin II blockade: a therapeutic strategy with wide applications. Clin Cardiol 26 (2003) 500-502
78. Hsueh W.A., and Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92 (2003) 10J-17J
79. Carlsson P.O., Bernie C., and Jansson L. Angiotensin II and the endocrine pancreas; effects on islet blood flow and insulin secretion in rats. Diabetologia 41 2 (1998) 127-133
80. Henriksen E.J., and Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 5 4 (2003) 214-222
81. Henriksen E.J., Jacob S., Kinnick T.R., et al. ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 277 1 Pt. 2 (1999) R332-R336
82. Lindholm L.H., Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a north of Sweden efficacy evaluation (ALPINE study). J Hypertens 21 8 (2003) 1563-1574
83. Azizi M., Linhart A., Alexander J., et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18 (2000) 1139-1147
84. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
85. Ruilope L.M., Aldigier J.C., Ponticelli C., et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18 1 (2000) 89-95
86. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
87. Teo K., Yusuf S., Sleight P., et al. ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
88. Diener H.C., Sacco R., Yusuf S., et al., Steering Committee; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS). Cerebrovasc Dis 23 (2007) 368-380
89. McMurray J.J., Carson P.E., Komajda M., et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 10 (2008) 149-156
90. Haller H., Viberti G.C., Mimran A., et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 24 2 (2006) 403-408